Published 2018
| Version v1
Publication
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)
Creators
- Taramasso L.
- Tatarelli P.
- Ricci E.
- Madeddu G.
- Menzaghi B.
- Squillace N.
- De Socio G. V.
- Martinelli C.
- Gulminetti R.
- Maggi P.
- Orofino G.
- Vichi F.
- Di Biagio A.
- Bonfanti P.
- Bellacosa C.
- Calza L.
- Abeli C.
- Celesia B. M.
- Grosso C.
- Stagno A.
- Mazzotta F.
- Penco G.
- Cassola G.
- Nicolini L. A.
- Dentone C.
- Molteni C.
- Palvarini L.
- Scalzini A.
- Carenzi L.
- Rizzardini G.
- Valsecchi L.
- Cordier L.
- Rusconi S.
- Colombo V.
- Galli M.
- Franzetti M.
- Sgrelli A.
- Mazzotta E.
- Parruti G.
- Bagella P.
- Mura M. S.
- Libertone R.
- Antinori A.
- Di Giambenedetto S.
- Guastavigna M.
- Caramello P.
Contributors
Others:
- Taramasso, L.
- Tatarelli, P.
- Ricci, E.
- Madeddu, G.
- Menzaghi, B.
- Squillace, N.
- De Socio, G. V.
- Martinelli, C.
- Gulminetti, R.
- Maggi, P.
- Orofino, G.
- Vichi, F.
- Di Biagio, A.
- Bonfanti, P.
- Bellacosa, C.
- Calza, L.
- Abeli, C.
- Celesia, B. M.
- Grosso, C.
- Stagno, A.
- Mazzotta, F.
- Penco, G.
- Cassola, G.
- Nicolini, L. A.
- Dentone, C.
- Molteni, C.
- Palvarini, L.
- Scalzini, A.
- Carenzi, L.
- Rizzardini, G.
- Valsecchi, L.
- Cordier, L.
- Rusconi, S.
- Colombo, V.
- Galli, M.
- Franzetti, M.
- Sgrelli, A.
- Mazzotta, E.
- Parruti, G.
- Bagella, P.
- Mura, M. S.
- Libertone, R.
- Antinori, A.
- Di Giambenedetto, S.
- Guastavigna, M.
- Caramello, P.
Description
Background: Dyslipidemia represents a significant non-infectious comorbidity among people living with HIV. The aim of this study is to evaluate the impact on lipid profile of switches from an efavirenz (EFV) or protease inhibitor/ritonavir (PI/r)-based regimen to a rilpivirine (RPV) or a once-daily integrase inhibitor-based regimen. Methods: We analyzed data from SCOLTA prospective database. All patients with HIV-RNA < 50 copies/ml in therapy with two NRTI + EFV or PI/r were included if they switched from EFV to dolutegravir (group EFV-DTG), elvitegravir (EFV-EVG), or RPV (EFV-RPV) and from PI/r to DTG (PI/r-DTG), PI/r to EVG (PI/r-EVG), or PI/r to RPV (PI/r-RPV). Total cholesterol (TC), TC/HDL ratio, LDL-cholesterol (LDL) and triglycerides (TG) were compared at baseline, six months and one year. Comparisons among groups were performed by a general linear model. Results: Four hundred and ninety patients were enrolled, 24.9% female, mean age 47.3 years (±10.1). According to ART switch, 11.4% were classified in group EFV-DTG, 3.9% in EFV-EVG, 23.9% in EFV-RPV, 17.6% in PI/r-DTG, 17.8% in PI/r-EVG, and 25.5% in PI/r-RPV. After adjusted analysis, TC significantly decreased in all groups but EFV-EVG, TC/HDL in all but EFV-DTG and EFV-EVG, while the reduction of TG was significant only in switches to RPV (EFV-RPV and PI/r-RPV). The one year decrease of TC, TC/HDL, LDL and TG was higher in patients with higher baseline levels of the same variable (p < .0001 for all). Conclusions: In SCOLTA, all switches from PI/r regimens gave advantages on lipid profile, while stopping EFV had consistently favorable lipid effects only if replaced by RPV.
Additional details
Identifiers
- URL
- http://hdl.handle.net/11567/954237
- URN
- urn:oai:iris.unige.it:11567/954237
Origin repository
- Origin repository
- UNIGE